EDAP Reports Strong Second Quarter 2025 HIFU Results
Rhea-AI Summary
EDAP TMS SA (NASDAQ: EDAP) reported strong Q2 2025 results, highlighted by exceptional growth in its core HIFU business. The company achieved 76.8% year-over-year HIFU revenue growth to EUR 8.5 million, driven by nine Focal One system sales versus three in Q2 2024. Total revenue reached EUR 16.0 million, up 1.6% year-over-year.
Key developments include a 36 million Euro credit facility letter of intent with the European Investment Bank and increased 2025 HIFU revenue growth guidance to 26-34% from previous 16-25%. The company reported a Q2 2025 net loss of EUR 5.6 million (EUR 0.15 per share), improved from EUR 6.1 million loss in Q2 2024.
EDAP's strategic focus on its high-margin HIFU business resulted in improved gross margins of 42.5% in Q2 2025, up from 37.5% in Q2 2024, while the company continues planned reduction of non-core ESWL and Distribution operations.
Positive
- HIFU revenue grew 76.8% year-over-year to EUR 8.5 million
- Secured 36 million Euro credit facility letter of intent with EIB
- Increased 2025 HIFU revenue growth guidance to 26-34%
- Improved gross margin to 42.5% from 37.5% year-over-year
- Placed 12 Focal One systems, representing 140% net placement growth
- 23.9% growth in worldwide disposable revenue
- Reduced net loss to EUR 5.6 million from EUR 6.1 million year-over-year
Negative
- Operating expenses increased to EUR 12.6 million from EUR 12.1 million
- Cash position decreased to EUR 16.3 million from EUR 22.8 million in Q1
- Non-core business revenue declined 30.9% to EUR 7.6 million
- First half 2025 net loss increased to EUR 12.7 million from EUR 10.7 million year-over-year
News Market Reaction
On the day this news was published, EDAP gained 15.19%, reflecting a significant positive market reaction. Argus tracked a peak move of +27.2% during that session. Argus tracked a trough of -26.1% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $86M at that time. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
- +
140% Focal One® Net Placement Growth Year over Year - +
76.8% HIFU Revenue Growth Year over Year - 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion
- Company raises 2025 HIFU Year over Year Revenue Growth Guidance range to
26% to34% , up from the prior range of16% to25%
Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT
AUSTIN, Texas, August 28, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the second quarter of 2025.
“We experienced our strongest second quarter performance in our company’s history, placing a net total of 12 Focal One Robotic HIFU Systems with increased customer demand coming from both U.S. and international markets,” said Ryan Rhodes, Chief Executive Officer. “The strong year over year growth in the second quarter underscores the accelerating momentum of our leading Focal One platform and its increased adoption amongst urologists. To continue to advance the expansion of Focal One, including new indications and further development of focused ultrasound technologies, we executed a letter of intent with the European Investment Bank that will provide a significant source of low interest rate capital. As we enter the second half of 2025, our Focal One pipeline continues to strengthen, and we anticipate demand for Focal One continuing to grow as more prostate cancer patients recognize the advantages of the Focal One treatment. This momentum is further supported by the groundbreaking publication from the large multicenter prospective comparative HIFI study and the compelling Level 1 clinical evidence from the FARP Randomized Controlled Trial, both of which are gaining wider dissemination within the global urology community.”
Business Update
- On August 26, 2025, the Company announced a letter of intent for credit facility with the European Investment Bank (EIB) for 36 million Euros
- On July 1, 2025, the Company announced that, effective January 1, 2026, EDAP will become a U.S. domestic filer and will begin complying with corresponding U.S. SEC reporting rules and Nasdaq listing requirements
- On April 29, 2025, the Company announced that the positive final 3-year outcomes of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) were presented at the 120th AUA Annual Meeting
- On April 24, 2025, the Company announced the launch of the new Focal One i Robotic HIFU System
Upcoming Meetings and Events
EDAP management will attend and present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference, in New York City from September 8-10, 2025. The Company is scheduled to present on September 9th from 8:30AM - 9:00AM ET and will also conduct 1x1 investor meetings. Click https://journey.ct.events/view/ede7e5df-b6f5-4ffb-a947-50a936dfb93b to register for the EDAP webcast.
2025 Financial Guidance
The Company is updating its 2025 financial guidance. Core HIFU business revenue is now expected to grow within the range of
Second Quarter 2025 Results
Total revenue in the HIFU business for the second quarter of 2025 was EUR 8.5 million (USD 9.7 million), as compared to EUR 4.8 million (USD 5.2 million) for the second quarter of 2024, representing growth of +
Total revenue in the Company’s non-core business (ESWL and Distribution) for the second quarter of 2025 was EUR 7.6 million (USD 8.7 million), as compared to EUR 11.0 (USD 11.8 million) for the second quarter of 2024. The decline in non-core business revenue was expected based on the Company’s strategic decision to focus exclusively on the high growth opportunity in focal therapy with the Focal One Robotic HIFU platform.
Total worldwide revenue for the second quarter of 2025 was EUR 16.0 million (USD 18.4 million), an increase of
Gross profit for the second quarter of 2025 was EUR 6.8 million (USD 7.8 million), compared to gross profit of EUR 5.9 million (USD 6.4 million) for the year-ago period. Gross profit margin on net sales was
Operating expenses were EUR 12.6 million (USD 14.5 million) for the second quarter, compared to EUR 12.1 million (USD 13.0 million) for the same period in 2024. The increase in operating expenses was primarily due to focused investments in our HIFU business.
Operating loss for the second quarter of 2025 was EUR 5.8 million (USD 6.6 million), compared to an operating loss of EUR 6.1 million (USD 6.6 million) in the second quarter of 2024.
Net loss for the second quarter of 2025 was EUR 5.6 million (USD 6.4 million), or EUR (0.15) per share, as compared to net loss of EUR 6.1 million (USD 6.6 million), or EUR (0.16) per share in the second quarter of 2024.
First Half 2025 Results
Total revenue in the HIFU business for the six months ended June 30, 2025, was EUR 14.7 million (USD 16.1 million), an increase of
Total revenue in the Company’s non-core business (ESWL and Distribution) business for the six months ended June 30, 2025, was EUR 15.0 million (USD 16.5 million), a
Total worldwide revenue for the six months ended June 30, 2025, was EUR 29.6 million (USD 32.6 million), a decrease of
Gross profit for the six months ended June 30, 2025, was EUR 12.5 million (USD 13.8 million), compared to EUR 12.3 million (USD 13.3 million), for the six months ended June 30, 2024. Gross profit margin on net sales was
Operating expenses were EUR 24.3 million (USD 26.7 million) for the six months ended June 30, 2025, compared to EUR 23.3 million (USD 25.1 million) for the same period in 2024.
Operating loss for the six months ended June 30, 2025, was EUR 11.8 million (USD 13.0 million), compared to an operating loss of EUR 11.0 million (USD 11.8 million) for the six months ended June 30, 2024.
Net loss for the six months ended June 30, 2025, was EUR 12.7 million (USD 14.0 million), or EUR (0.34) per share, as compared to a net loss of EUR 10.7 million (USD 11.5 million), or EUR (0.29) per share for the six months ended June 30, 2024.
As of June 30, 2025, the Company held cash and cash equivalents of EUR 16.3 million (USD 19.1 million) as compared to EUR 22.8 million (USD 24.6 million) as of March 31, 2025.
Conference Call Information
A conference call and webcast to discuss the second quarter 2025 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Date: Thursday, August 28th @ 8:30am Eastern Time
Domestic: 1-800-274-8461
International: 1-203-518-9814
Passcode (Conf ID): EDAP
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1726716&tp_key=220919ac3d
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements include our expectations to enter into a credit facility with EIB, the size thereof, the timing thereof and the use of proceeds from such credit facility. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| | | | | | | | | |
| | | Three Months Ended: | | Three Months Ended: | ||||
| | June 30, | June 30, | June 30, | June 30, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Sales of medical equipment | 11,221 | 11,118 | 12,891 | 11,948 | ||||
| Net sales of RPP and leases | 2,246 | 1,886 | 2,580 | 2,027 | ||||
| Sales of spare parts, supplies and services | 2,576 | 2,787 | 2,960 | 2,995 | ||||
| TOTAL REVENUES | 16,043 | 15,791 | 18,431 | 16,970 | ||||
| Cost of sales | (9,221) | (9,872) | (10,594) | (10,609) | ||||
| GROSS PROFIT | 6,822 | 5,919 | 7,838 | 6,361 | ||||
| Research & development expenses | (2,208) | (2,077) | (2,537) | (2,232) | ||||
| Selling, general & administrative expenses | (10,382) | (9,989) | (11,928) | (10,736) | ||||
| Total operating expenses | (12,591) | (12,066) | (14,465) | (12,967) | ||||
| OPERATING LOSS | (5,769) | (6,147) | (6,628) | (6,606) | ||||
| Interest (expense) income, net | (57) | 190 | (66) | 204 | ||||
| Currency exchange gains (loss), net | 319 | (49) | 367 | (52) | ||||
| LOSS BEFORE INCOME TAXES | (5,507) | (6,005) | (6,327) | (6,454) | ||||
| Income tax (expense) credit, net | (93) | (127) | (107) | (136) | ||||
| NET LOSS | (5,600) | (6,132) | (6,434) | (6,590) | ||||
| Earning per share – basic and diluted | (0.15) | (0.16) | (0.17) | (0.18) | ||||
| Average number of shares used in computation of basic and diluted EPS | 37,420,318 | 37,205,307 | 37,420,318 | 37,205,307 | ||||
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average three months’ exchange rate of 1 Euro = 1.1489 USD, and 2024 average three months’ exchange rate of 1 Euro = 1.0747 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
| | | | | | | | | |
| | | Six Months Ended: | | Six Months Ended: | ||||
| | June 30, | June 30, | June 30, | June 30, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Sales of medical equipment | 20,184 | 21,085 | 22,224 | 22,735 | ||||
| Net sales of RPP and leases | 4,406 | 3,661 | 4,851 | 3,948 | ||||
| Sales of spare parts, supplies and services | 5,011 | 5,952 | 5,518 | 6,418 | ||||
| TOTAL REVENUES | 29,601 | 30,698 | 32,593 | 33,102 | ||||
| Cost of sales | (17,084) | (18,394) | (18,811) | (19,834) | ||||
| GROSS PROFIT | 12,517 | 12,304 | 13,782 | 13,267 | ||||
| Research & development expenses | (4,663) | (4,146) | (5,134) | (4,470) | ||||
| Selling, general & administrative expenses | (19,619) | (19,121) | (21,602) | (20,618) | ||||
| Total operating expenses | (24,282) | (23,267) | (26,736) | (25,088) | ||||
| OPERATING LOSS | (11,765) | (10,963) | (12,954) | (11,821) | ||||
| Interest (expense) income, net | (43) | 335 | (47) | 361 | ||||
| Currency exchange gains (loss), net | (637) | 187 | (701) | 202 | ||||
| LOSS BEFORE INCOME TAXES | (12,444) | (10,440) | (13,702) | (11,258) | ||||
| Income tax (expense) credit, net | (230) | (238) | (253) | (257) | ||||
| NET LOSS | (12,674) | (10,678) | (13,955) | (11,514) | ||||
| Earning per share – basic and diluted | (0.34) | (0.29) | (0.37) | (0.31) | ||||
| Average number of shares used in computation of basic and diluted EPS | 37,406,202 | 37,104,348 | 37,406,202 | 37,104,348 | ||||
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average six months’ exchange rate of 1 Euro = 1.1011 USD, and 2024 average six months’ exchange rate of 1 Euro = 1.0783 USD
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of Euros and U.S. Dollars)
| | | | | | | | | |
| | June 30, | December 31, | June 30, | December 31, | ||||
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | Euros | | Euros | | $US | | $US |
| Cash, cash equivalents and short-term investments | 16,265 | 29,836 | 19,144 | 30,883 | ||||
| Accounts receivable, net | 18,527 | 20,288 | 21,806 | 21,000 | ||||
| Inventory | 15,531 | 18,495 | 18,281 | 19,143 | ||||
| Other current assets | 1,157 | 1,258 | 1,362 | 1,302 | ||||
| TOTAL CURRENT ASSETS | 51,480 | 69,876 | 60,593 | 72,328 | ||||
| Property, plant and equipment, net | 10,202 | 10,336 | 12,009 | 10,699 | ||||
| Goodwill | 2,412 | 2,412 | 2,839 | 2,496 | ||||
| Other non-current assets | 4,248 | 3,439 | 5,000 | 3,560 | ||||
| TOTAL ASSETS | 68,343 | 86,063 | 80,441 | 89,083 | ||||
| Accounts payable & other accrued liabilities | 18,549 | 21,350 | 21,833 | 22,099 | ||||
| Deferred revenues, current portion | 5,898 | 6,641 | 6,942 | 6,874 | ||||
| Short term borrowing | 6,276 | 6,243 | 7,387 | 6,462 | ||||
| Other current liabilities | 3,392 | 3,577 | 3,993 | 3,702 | ||||
| TOTAL CURRENT LIABILITIES | 34,115 | 37,811 | 40,154 | 39,138 | ||||
| Obligations under operating and finance leases non-current | 1,660 | 1,939 | 1,954 | 2,007 | ||||
| Long-term debt, non-current | 1,022 | 2,162 | 1,203 | 2,238 | ||||
| Deferred revenues, non-current | 718 | 358 | 845 | 370 | ||||
| Other long-term liabilities | 3,006 | 2,897 | 3,538 | 2,999 | ||||
| TOTAL LIABILITIES | 40,521 | 45,167 | 47,694 | 46,752 | ||||
| TOTAL SHAREHOLDERS’EQUITY | 27,822 | 40,896 | 32,747 | 42,331 | ||||
| TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY | 68,343 | 86,063 | 80,441 | 89,083 |
NOTE: Translated for convenience of the reader to U.S. dollars at the exchange rate of 1 Euro = 1.1770 USD, on June 30, 2025 and at the exchange rate of 1 Euro = 1.0351 USD, on December 31, 2024.
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of Euros and U.S. Dollars)
| | | | | | | | | |
| | Six Months Ended | Twelve Months Ended | Six Months Ended | Twelve Months Ended | ||||
| | | June 30, | | December 31, | | June 30, | | December 31, |
| | | 2025 | | 2024 | | 2025 | | 2024 |
| | | (Euros) | | (Euros) | | ($US) | | ($US) |
| NET INCOME (LOSS) | (12,674) | (19,018) | (13,955) | (20,520) | ||||
| Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) | 2,767 | 7,395 | 3,046 | 7,979 | ||||
| OPERATING CASH FLOW | (9,907) | (11,623) | (10,909) | (12,541) | ||||
| Increase/Decrease in operating assets and liabilities | 713 | (1,961) | 785 | (2,116) | ||||
| NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES | (9,194) | (13,584) | (10,123) | (14,657) | ||||
| Additions to capitalized assets produced by the company and other capital expenditures | (2,669) | (4,120) | (2,939) | (4,445) | ||||
| NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES | (2,669) | (4,120) | (2,939) | (4,445) | ||||
| NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES | (1,096) | 4,635 | (1,207) | 5,001 | ||||
| NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (611) | (566) | 2,531 | (3,103) | ||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (13,571) | (13,635) | (11,738) | (17,204) |
(1) including share based compensation expenses for 775 thousand of Euros for the six months ended June 30, 2025 and 3,283 thousand of Euros for the full year ended December 31, 2024.
NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average six months’ exchange rate of 1 Euro = 1.1011 USD, and 2024 average twelve months exchange rate of 1 Euro = 1.0790 USD
EDAP TMS S.A.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
six months ended June 30, 2025
(Amounts in thousands of Euros)
| | | | | | | | | | | | | | | | | | | | |
| | HIFU | ESWL | Distribution | Reconciling | Total After | ||||||||||||||
| | | Division | | | | Division | | | | Division | | | | Items | | Consolidation | | | |
| Sales of medical equipment | 9,321 | 681 | 10,181 | — | 20,184 | | |||||||||||||
| Net sales of RPP and leases | 3,752 | 538 | 117 | — | 4,406 | | |||||||||||||
| Sales of spare parts, supplies and services | 1,578 | 2,069 | 1,365 | — | 5,011 | | |||||||||||||
| TOTAL REVENUES | 14,650 | 3,288 | 11,663 | — | 29,601 | | |||||||||||||
| GROSS PROFIT (% of Net Sales) | 7,339 | 50.1 | % | 1,468 | 44.6 | % | 3,710 | 31.8 | % | — | 12,517 | 42.3 | % | ||||||
| Research & development expenses | (4,254) | (84) | (325) | — | (4,663) | | |||||||||||||
| Selling, general & administrative expenses | (13,248) | (507) | (4,035) | (1,828) | (19,619) | | |||||||||||||
| OPERATING PROFIT (LOSS) | (10,163) | 876 | (650) | (1,828) | (11,765) | |
Attachment
FAQ
What were EDAP's Q2 2025 HIFU revenue and growth?
How much is the European Investment Bank credit facility for EDAP?
What is EDAP's updated HIFU revenue guidance for 2025?
How many Focal One systems did EDAP place in Q2 2025?
What was EDAP's Q2 2025 net loss per share?
How much cash does EDAP have as of Q2 2025?
